Prognostic Value of MicroRNA-15a in Human Cancers: A Meta-Analysis and Bioinformatics

Overview

Journal Biomed Res Int

Publisher Wiley

Specialties Biomedical Engineering
Biotechnology
General Medicine

Date 2019 May 8

PMID 31061821

Citations 8

Authors

Fei-Ran Yang

Hui-Jie Li

Ting-Ting Li

Yu-Feng Zhao

Zong-Kai Liu

Xiu-Rong Li

Affiliations

Soon will be listed here.

Abstract

Background: Although several studies have proved the relationship between the prognostic value of miRNA-15a and different types of cancer, the result remains controversial. Thus, a meta-analysis was conducted to clarify the prognostic value of miRNA-15a expression level in human cancers.

Methods: We enrolled appropriate literature by searching the databases of PubMed, Embase, and Web of Science. Subsequently, we extracted HRs and their 95% CIs and calculated pooled results of miRNA-15a for overall survival (OS) and disease-free survival (DFS). Besides, subgroup analysis, sensitivity analysis, and publication bias were also revealed in this study. We also further validated this meta-analysis using the Kaplan-Meier plotter database.

Result: 10 studies, including 1616 patients, were embraced in our meta-analysis. The result showed the lower expression of miRNA-15a significantly predicted adverse OS (HR=2.17, 95% CI: 1.41-3.34), but there is no significant association between the expressing level and DFS in cancer patient (HR=2.04, 95% CI: 0.60-6.88). Based on Kaplan-Meier plotter database, we found the same results in bladder Carcinoma, head-neck squamous cell carcinoma, liver hepatocellular carcinoma, lung squamous cell carcinoma, pancreatic ductal adenocarcinoma, rectum adenocarcinoma, stomach adenocarcinoma, and uterine corpus endometrial carcinoma, but opposite results were found in cervical squamous cell carcinoma and esophageal carcinoma.

Conclusion: Low expressing levels of miRNA-15a indicated poor OS, while miRNA-15a can be used as a prediction biomarker in different cancer types.

Citing Articles

Non-coding RNAs and gastrointestinal cancers prognosis: an umbrella review of systematic reviews and meta-analyses of observational studies.

Zha B, Luo Y, Kamili M, Zha X Front Oncol. 2023; 13:1193665.

PMID: 37546412 PMC: 10399243. DOI: 10.3389/fonc.2023.1193665.

The dynamic tumor-stromal crosstalk: implications of 'stromal-hot' tumors in the process of epithelial-mesenchymal transition in breast cancer.

Mavatkar A, Naidu C, Prabhu J, Nair M Mol Biol Rep. 2023; 50(6):5379-5393.

PMID: 37046108 DOI: 10.1007/s11033-023-08422-4.

Diagnostic implication of a circulating serum-based three-microRNA signature in hepatocellular carcinoma.

Yousuf T, Dar S, Bangri S, Choh N, Rasool Z, Shah A Front Genet. 2022; 13:929787.

PMID: 36457743 PMC: 9705795. DOI: 10.3389/fgene.2022.929787.

Bioinformatics-based identification of miRNAs, mRNA, and regulatory signaling pathways involved in esophageal squamous cell carcinoma.

Askari N, Hadizadeh M Gastroenterol Hepatol Bed Bench. 2022; 15(3):232-240.

PMID: 36311956 PMC: 9589132. DOI: 10.22037/ghfbb.v15i3.2465.

Prognostic Impact of Serum CRP Level in Head and Neck Squamous Cell Carcinoma.

Zhang Y, Gu D Front Oncol. 2022; 12:889844.

PMID: 35847918 PMC: 9277075. DOI: 10.3389/fonc.2022.889844.

References

Bartel D . MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004; 116(2):281-97. DOI: 10.1016/s0092-8674(04)00045-5. View

Cimmino A, Calin G, Fabbri M, Iorio M, Ferracin M, Shimizu M . miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A. 2005; 102(39):13944-9. PMC: 1236577. DOI: 10.1073/pnas.0506654102. View

Esquela-Kerscher A, Slack F . Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006; 6(4):259-69. DOI: 10.1038/nrc1840. View

Kloosterman W, Plasterk R . The diverse functions of microRNAs in animal development and disease. Dev Cell. 2006; 11(4):441-50. DOI: 10.1016/j.devcel.2006.09.009. View

Tierney J, Stewart L, Ghersi D, Burdett S, Sydes M . Practical methods for incorporating summary time-to-event data into meta-analysis. Trials. 2007; 8:16. PMC: 1920534. DOI: 10.1186/1745-6215-8-16. View

Cho W . OncomiRs: the discovery and progress of microRNAs in cancers. Mol Cancer. 2007; 6:60. PMC: 2098778. DOI: 10.1186/1476-4598-6-60. View

Aqeilan R, Calin G, Croce C . miR-15a and miR-16-1 in cancer: discovery, function and future perspectives. Cell Death Differ. 2009; 17(2):215-20. DOI: 10.1038/cdd.2009.69. View

Bhattacharya R, Nicoloso M, Arvizo R, Wang E, Cortez A, Rossi S . MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res. 2009; 69(23):9090-5. PMC: 2859686. DOI: 10.1158/0008-5472.CAN-09-2552. View

Moher D, Liberati A, Tetzlaff J, Altman D . Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg. 2010; 8(5):336-41. DOI: 10.1016/j.ijsu.2010.02.007. View

10.

Heneghan H, Miller N, Kerin M . MiRNAs as biomarkers and therapeutic targets in cancer. Curr Opin Pharmacol. 2010; 10(5):543-50. DOI: 10.1016/j.coph.2010.05.010. View

11.

Musumeci M, Coppola V, Addario A, Patrizii M, Maugeri-Sacca M, Memeo L . Control of tumor and microenvironment cross-talk by miR-15a and miR-16 in prostate cancer. Oncogene. 2011; 30(41):4231-42. DOI: 10.1038/onc.2011.140. View

12.

Bandi N, Vassella E . miR-34a and miR-15a/16 are co-regulated in non-small cell lung cancer and control cell cycle progression in a synergistic and Rb-dependent manner. Mol Cancer. 2011; 10:55. PMC: 3120797. DOI: 10.1186/1476-4598-10-55. View

13.

Hullinger T, Montgomery R, Seto A, Dickinson B, Semus H, Lynch J . Inhibition of miR-15 protects against cardiac ischemic injury. Circ Res. 2011; 110(1):71-81. PMC: 3354618. DOI: 10.1161/CIRCRESAHA.111.244442. View

14.

Esteller M . Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12):861-74. DOI: 10.1038/nrg3074. View

15.

Huang Y, Lin K, Chen H, Chang M, Hsu C, Lai M . Identification of postoperative prognostic microRNA predictors in hepatocellular carcinoma. PLoS One. 2012; 7(5):e37188. PMC: 3358336. DOI: 10.1371/journal.pone.0037188. View

16.

Chen C, Chen C, Chen J, Zhou L, Xu H, Jin W . Histone deacetylases inhibitor trichostatin A increases the expression of Dleu2/miR-15a/16-1 via HDAC3 in non-small cell lung cancer. Mol Cell Biochem. 2013; 383(1-2):137-48. DOI: 10.1007/s11010-013-1762-z. View

17.

Luo Q, Li X, Li J, Kong X, Zhang J, Chen L . MiR-15a is underexpressed and inhibits the cell cycle by targeting CCNE1 in breast cancer. Int J Oncol. 2013; 43(4):1212-8. DOI: 10.3892/ijo.2013.2034. View

18.

Guo S, Xu X, Tang Y, Zhang C, Li J, Ouyang Y . miR-15a inhibits cell proliferation and epithelial to mesenchymal transition in pancreatic ductal adenocarcinoma by down-regulating Bmi-1 expression. Cancer Lett. 2013; 344(1):40-46. DOI: 10.1016/j.canlet.2013.10.009. View

19.

Pekarsky Y, Croce C . Role of miR-15/16 in CLL. Cell Death Differ. 2014; 22(1):6-11. PMC: 4262785. DOI: 10.1038/cdd.2014.87. View

20.

Xiao G, Tang H, Wei W, Li J, Ji L, Ge J . Aberrant Expression of MicroRNA-15a and MicroRNA-16 Synergistically Associates with Tumor Progression and Prognosis in Patients with Colorectal Cancer. Gastroenterol Res Pract. 2014; 2014:364549. PMC: 4236961. DOI: 10.1155/2014/364549. View